🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being viewed as a "major milestone" in the battle against increasingly resistant strains of the pathogen, according to scientists.

A Worldwide Challenge

The sexually transmitted infection are escalating worldwide, with data suggesting in excess of 82 million infections each year. Notably increased rates are observed in Africa and nations within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were three times higher compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely advancement in the reality of growing infection rates, the spread of superbugs and the highly restricted therapeutic options at this time.”

Public health authorities are deeply concerned about the increase in antibiotic-resistant strains. The World Health Organization has designated it as a "high-priority threat". Ongoing monitoring revealed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Recent Drugs Gain Approval

One new antibiotic, also known as Nuzolvence, was approved by the American regulatory agency in recent days for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers hope that specific application of this new drug will help slow the development of resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in the same week. This drug, which is additionally indicated for urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Unique Development Model

Zoliflodacin was the result of a new, not-for-profit approach for drug creation. The non-profit organisation GARDP collaborated with the drug firm its industry partner to see it through.

“This authorization marks a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Research Study Results and Global Access

According to findings detailed in a prominent scientific publication, the new drug successfully treated more than 90% of genital gonorrhoea infections. This places it at an equal footing with the typical regimen, which uses an injection and a pill. The research included hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its unique model, GARDP has the ability to license and sell the drug in numerous developing nations.

Medical professionals directly involved have expressed hope. The availability of a single-dose, oral treatment like this is described as a "revolutionary step" for public health efforts. This is deemed crucial to lessen the impact of the infection for patients and to halt the transmission of extremely resistant gonorrhoea globally.